Standard guidelines for treating metastatic prostate cancer are based on conventional imaging (CT/bone scan). The panel argues that PSMA PET-positive biochemical recurrence represents a different, earlier disease state. This necessitates new treatment paradigms, like definitive therapy durations, not covered by current guidelines.

A meta-analysis of over 9,500 patients in major prostate cancer trials, including the pivotal VISION and PSMA-4 trials for radioligand therapy, shows significant underrepresentation of Black and Hispanic patients. This creates a critical evidence gap when applying these therapies to diverse real-world populations.

The NCI working group concluded that neither metastasis-directed therapy (MDT) nor systemic hormonal therapy should be required as a control arm in trials for biochemically recurrent (BCR) prostate cancer. This facilitates testing novel non-hormonal agents and reflects that surveillance is often a reasonable standard of care.

A key lesson from radium-223 trials is the critical need for concurrent bone protective agents. Protocol amendments adding these agents eliminated an excess of osteoporotic fractures. This requires only osteoporosis prevention dosing (e.g., yearly zoledronic acid), not the more frequent dosing used for skeletal-related events.

Even within recent major clinical trials like HER2CLIMB-05, less than half of eligible hormone receptor-positive patients received endocrine therapy. This highlights a critical and widespread gap in clinical practice, as this treatment adds significant benefit.

The influential "2+2 rule" on bone scans, which accounts for treatment "flare," wasn't an arbitrary threshold. It was proposed as a working hypothesis to be tested and validated through numerous clinical trials. This exemplifies the data-driven, iterative process behind the PCWG criteria.

Experts believe molecular tests like Decipher and PTEN status are superior to simply counting bone lesions for guiding treatment. While not yet standard practice for all decisions, this represents a significant shift towards using underlying tumor biology to determine therapy, like adding docetaxel.

In the AMPLITUDE trial, only 16% of high-risk metastatic prostate cancer patients received docetaxel, despite it being allowed and indicated by disease characteristics. This suggests a real-world "chemophobia" or physician bias towards newer targeted therapies, even within a clinical trial setting.

PCWG4 replaces terms like "castration-resistant" with "Androgen Pathway Modulation (APM) resistant." This change is driven by patient feedback finding the term "castration" insensitive and by the need for language that reflects modern treatments that don't always involve medical or surgical castration.